Organic Chemistry Methods TRIZ Cases

Controlled crystallization and salt selection make pralsetinib more suitable for stable oral formulations with consistent solid-form properties.

Controlled crystallization creates c-Met inhibitor form B with improved bioavailability, stability, solubility, and lower hygroscopicity.

Using chiral tert-butyl sulfinamide avoids costly chiral catalysts and shortens nicotine synthesis while maintaining high yield and ee.

High-purity oxygen and dry gas sealing suppress argon buildup in ethylene oxide circulation gas, reducing purge loss and pressure drift.

A central chiral fragment drives rigid spiro tetradentate Pt/Pd complexes that avoid racemization and chiral resolution while sustaining stable CPL emission.

A defined crystalline intermediate improves control of MDM2-p53 inhibition and supports p53 activation in treatment of p53 wild-type tumors.

Low-palladium cross-coupling and crystallization cut impurities and cost while improving SRA737 yield for large-scale manufacture.

Oxalic acid and controlled heating keep radioactive zirconium soluble, improving DOTA or NOTA complex yield for PET microdosing.

A host-dopant organic compound system improves color purity, luminescence efficiency, heat resistance, and element lifetime at lower driving voltage.

Specific salt and freebase forms of a WEE1 inhibitor improve delivery and stability to disrupt the G2-M checkpoint and sensitize tumors to DNA damage.

Tailored organometallic OLED materials produce saturated RGB light directly, improving color accuracy and reducing reliance on absorption filters.

A novel ionizable lipid structure improves mRNA encapsulation and tissue targeting while reducing formulation optimization complexity.

Small-molecule GnRHR ligands guide radionuclides to receptor-overexpressing tumors, improving treatment specificity and imaging while sparing healthy tissue.

Multiple hydrobromide solid forms balance stability, solubility, hygroscopicity, and manufacturability for oral gamma-secretase inhibitors.

Crystallizing sodium lactate melt on a seeded cooling surface creates low-water solid particles that stay non-tacky and free-flowing.

Multiple crystalline and amorphous forms of a CDK4/6 inhibitor improve solubility, stability, and bioavailability for cancer formulations.

Allyl ether resin chemistry replaces residual hydroxyl groups to improve heat resistance, dielectric loss, and moisture stability in electronic packaging.

Nitrogen-containing heterocyclic compounds tune OLED layer energy levels and improve thermal and electrochemical stability for longer device life.

A two-layer OLED emission stack uses iridium and platinum dopants with tuned hole trap index to lower voltage and extend lifespan.

A commensal-bacteria metabolite activates CD8 T cells to inhibit tumor growth while avoiding the side effects and scale limits of antibodies or live bacteria.

Pressurized gas and 115-200°C solvent circulation speed polymer removal in reactors, cutting shutdown time and cleaning cost.

Controlled low-water alpha-cyclodextrin crystals stabilize sulforaphane under ambient humidity, easing storage, handling, and formulation.

Controlled crystallization creates stable IDH2 inhibitor polymorphs with consistent morphology, dissolution, and manufacturing quality.

Controlled ketone or ether solvent crystallization lowers free acid in meso-lactide while limiting lactic acid oligomer formation and yield loss.

Specific A2A antagonist crystal forms improve solubility and pharmacokinetics, enabling better tumor targeting and stronger anti-tumor immune response.

Specific pyridone crystal forms improve bioavailability, stability, and storage while maintaining strong inhibition of influenza A and B viruses.

Deuterated spiro-fluorene compounds in red emitting and hole transport layers raise OLED efficiency while extending lifespan.

β-thio carbonyl and nitrile compounds release odor molecules over time, improving fragrance intensity and wash-resistant substantivity on textiles.

Stable crystal forms A and B improve nitroxoline prodrug solubility and manufacturability while supporting less frequent dosing.

Novel heterocyclic derivatives modify kinase inhibitor scaffolds to treat cancer while delaying resistance in MAPK and EGFR pathways.

N-substituted indoles improve serotonin receptor compound pharmacokinetics and neuronal plasticity for neurologic and psychiatric treatment.

Controlled crystalline and amorphous hydrobromide salt forms improve stability, solubility, and manufacturability for oral cancer therapy.

A tailored organic EL compound improves electron and hole transport to cut driving voltage, raise efficiency, and extend OLED lifetime.

Controlled crystallization creates stable lipoprotein crystal forms and salts that reduce agglomeration and improve filtration and powder flow.

Crystallizing (-)-Ambrox during bioconversion enables simple filtration-based separation from impurities, improving purity, yield, and scalability.

A water-based acid- or organocatalyzed [3+3] cycloaddition makes this sotorasib intermediate in high yield and purity without hazardous solvents.

Plant-based ferulic acid and fermentation intermediates enable high-purity deoxycholic acid synthesis while avoiding animal contaminants.

Fused pyrido heterocycle emitters tune HOMO-LUMO levels to improve OLED color purity and transient response for saturated displays.

Selective PI3Kα inhibitors improve tumor target inhibition while reducing toxicity from non-selective PI3K isoform inhibition.

A tuned silica-alumina catalyst keeps propanol dehydration active in water-rich feedstocks while limiting C6 olefin by-products.

Targeting CXCR2 with a stable crystalline antagonist reduces neutrophil recruitment and improves pulmonary function in COPD models.

Small-molecule amide or urea compounds inhibit KIF18A to arrest CIN tumor cells and spare normal cell proliferation in cancer treatment.

A positive allosteric modulator paired with carvedilol boosts beta-arrestin cardioprotective signaling to reduce response variation in cardiovascular treatment.

A sublayered OLED emissive layer uses phosphorescence or TADF energy transfer to a narrowband emitter for high color purity, efficiency, and longer life.

Dynamic kinetic resolution combines enzyme selectivity with racemization to raise chiral hydroxypiperidine yield and enantiomeric excess.

Two blue emitting layers with different p-type host mobilities expand recombination, lowering OLED driving voltage and extending lifespan.

A mixed deuteration OLED composition boosts lifetime while avoiding the cost, complexity, and performance tradeoffs of full substitution.

Nitrogen-containing hole transport compounds lower OLED driving voltage while improving emission efficiency and extending device lifespan.

Wet-pulverizing or wet-kneading Formula (I) forms stable crystals and suppresses impurity Compound (III) in pharmaceutical compositions.